Study on the varieties included in the List of Overseas New Drugs Urgently Needed in Clinic in China and the optimization strategy
- VernacularTitle:我国《临床急需境外新药名单》纳入品种及优化策略研究
- Author:
Feng JIANG
1
;
Kan TIAN
2
Author Information
1. School of Health Economics and Management，Nanjing University of Chinese Medicine，Nanjing 210023，China
2. School of Elderly Care Service and Management，Nanjing University of Chinese Medicine，Nanjing 210023，China
- Publication Type:Journal Article
- Keywords:
List of Overseas New Drugs Urgently Needed in Clinic;
variety;
optimization strategy
- From:
China Pharmacy
2023;34(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To study the variety included in the List of Overseas New Drugs Urgently Needed in Clinic in China and optimization strategy， in order to better meet the needs of patients. METHODS The release process of List of Overseas New Drugs Urgently Needed in Clinic， the characteristics and attributes of the new drugs urgently needed abroad， and the problems in the implementation process were all analyzed to put forward some suggestions for optimizing the List of Overseas New Drugs Urgently Needed in Clinic. RESULTS & CONCLUSIONS The release process of the List of Overseas New Drugs Urgently Needed in Clinic was roughly divided into incubation stage， preparation stage and implementation stage. The treatment fields of 3 batches of overseas new drugs urgently needed in clinic were relatively concentrated on endocrine and metabolic diseases，tumor and skin diseases. Of included 73 varieties， 50 varieties have been approved for market，and 26 varieties have been included in the medical insurance， 4 varieties were included in the Catalogue of Encouraged Generic Drugs. At present， there are still some problems in our country， such as the shortage monitoring system needs to be established and improved； the linkage with medical insurance is weakened； the encouragement of generic drugs is insufficient. It is necessary to strengthen the cooperation of monitored departments in the shortage of new overseas drugs，establish a medical insurance payment system oriented by clinical value， and improve the incentive mechanism to encourage the imitation of overseas new drugs urgently needed in clinic.
